Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of NGEN.V is 6.9 and suggests 30% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell